olmesartan has been researched along with Diabetes Mellitus, Type 2 in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (21.21) | 29.6817 |
| 2010's | 48 (72.73) | 24.3611 |
| 2020's | 4 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Abo El-Nasr, NME; Hashad, IM; Saleh, DO | 1 |
| Hawkins, C; Kieu, Z; Kitazawa, M; Maitra, N; Mejias-Ortega, M; Nishiyama, A; Ortiz, RM; Peng, M; Rodriguez, R; Rodriguez-Ortiz, CJ; Thorwald, MA; Valenzuela, J | 1 |
| Abdelsalam, RM; Abo El-Nasr, NME; El-Abhar, HS; Mahmoud, SS; Nofal, SM; Safar, MM; Saleh, DO | 1 |
| Chatzikyrkou, C; Haller, H; Korda, A; Menne, JJ; Scurt, FG | 1 |
| Chatzikyrkou, C; Haller, H; Izzo, J; Menne, J; Mertens, PR; Rabelink, T; Ruilope, LM; Rump, C; Viberti, G | 1 |
| Dohi, Y; Hirota, H; Isaka, N; Ito, M; Kato, T; Kimura, G; Kojima, M; Machida, H; Makino, K; Miyagawa, K; Mizubayashi, R; Mizuno, O; Nakatani, K; Okamoto, S; Okubo, S; Okura, T; Takeuchi, M | 1 |
| Chan, JC; Haneda, M; Harada, A; Imai, E; Ito, S; Kobayashi, F; Makino, H; Yamasaki, T | 1 |
| Daikuhara, H; Fukunaga, K; Ohshima, T | 1 |
| Haller, H; Menne, J; Ott, C; Raff, U; Ruilope, LM; Schmieder, RE | 1 |
| Abe, M; Oikawa, O; Okada, K; Soma, M | 1 |
| Chan, C; Duru, OK; Ettner, SL; Ho, S; Keckhafer, AM; Kimbro, L; Kirvan, A; Li, J; Luchs, RH; Mangione, CM; Moin, T; Neugebauer, R; Turk, N | 1 |
| Ruilope, LM | 1 |
| Bakris, GL; Cuadra, RH; Kupfer, S; Lloyd, E; White, WB | 1 |
| Pichler, G; Redon, J | 2 |
| D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM | 1 |
| Chang, TT; Chen, JS; Chen, JW; Huang, PH; Lin, LY; Lin, SJ; Wu, TC | 1 |
| Böhm, M; Bramlage, P; Haller, H; Ruilope, LM; Schmieder, RE | 1 |
| Kario, K; Kushiro, T; Okuda, Y; Saito, I; Sato, Y; Shimada, K; Teramukai, S | 1 |
| Fukui, M; Hasegawa, G; Matsumoto, S; Nakamura, N; Oyabu, C; Tanaka, M; Ushigome, E; Ushigome, H; Yamazaki, M; Yokota, I | 1 |
| Dong, YF; Ichijo, H; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Nakaoka, H; Senba, I; Sone, H | 1 |
| García De La Villa, B; Tofé Povedano, S | 1 |
| Albert, PJ; Perez, TH; Waterhouse, JC | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Menne, J; Mimran, A; Rabelink, AJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, GC | 1 |
| Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T | 1 |
| Hayashi, T; Kitada, K; Kitaura, Y; Matsumoto, C; Matsumura, Y; Miyamura, M; Mori, T; Okada, Y; Sohmiya, K; Ukimura, A; Yamashita, C; Yoshioka, T | 1 |
| Kereiakes, DJ; Neutel, JM; Shojaee, A; Stoakes, KA; Waverczak, WF; Xu, J | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA | 1 |
| Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y | 1 |
| Bakris, G; Haller, H; Izzo, J; Oparil, S; Ruilope, L; Sowers, J; Waeber, B; Weber, M | 1 |
| Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Mimran, A; Rabelink, AJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Menne, J; Mimran, A; Rabelink, TJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G | 1 |
| Ingelfinger, JR | 1 |
| McInnes, GT | 1 |
| de Zeeuw, D; Heerspink, HJ; Roscioni, SS | 1 |
| Aessopos, A; Farmakis, D | 1 |
| Fioretto, P; Mauer, M | 1 |
| Krämer, BK; Krüger, B; Lammert, A | 1 |
| Lehman, R; Yudkin, JS | 1 |
| Abe, M; Maruyama, N; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M | 1 |
| Hayashi, K | 1 |
| Cohen, DL; Townsend, RR | 1 |
| Cascón, JD; Consuegra-Sánchez, L; Núñez, J; Picó, F; Sanchis, J; Villegas, M | 1 |
| Chan, JC; Haneda, M; Imai, E; Ito, S; Kobayashi, F; Makino, H; Yamasaki, T | 1 |
| Imai, E | 1 |
| Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A | 1 |
| Chatzykirkou, C; Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Menne, J; Mimran, A; Rabelink, TJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G | 1 |
| Arakawa, K; Jinnouchi, H; Jinnouchi, T; Kim-Mitsuyama, S; Matsui, K; Ogawa, H | 1 |
| Daikuhara, H; Ishida, T; Kikuchi, F | 1 |
| Araki, E; Furukawa, N; Goto, R; Ichimori, S; Ichinose, K; Iwashita, S; Kawashima, J; Maeda, T; Nishida, K; Shimoda, S; Tsuruzoe, K | 1 |
| Chatzikyrkou, C; Menne, J | 1 |
| Haller, H; Menne, J; Ritz, E | 1 |
| Arao, T; Mori, H; Nishida, K; Okada, Y; Tanaka, Y | 1 |
| Fukushima, A; Hirabayashi, K; Homma, T; Kadoguchi, T; Kinugawa, S; Masaki, Y; Mizushima, W; Okita, K; Ono, T; Sobirin, MA; Suga, T; Takada, S; Takahashi, M; Tsutsui, H; Yokota, T | 1 |
| Bahlmann, FH; de Groot, K; Fliser, D; Haller, H; Hertel, B; Mueller, O | 1 |
| Aso, Y; Inukai, T; Inukai, Y; Matsutomo, R; Nakamachi, T; Takahashi, K; Takanashi, K; Takebayashi, K; Wakabayashi, S; Yoshida, N | 1 |
| Halimi, S | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Mimran, A; Rabelink, AJ; Remuzzi, G; Ritz, E; Ruilope, LM; Rump, LC; Viberti, GC | 1 |
| Chen, R; Horiuchi, M; Iwai, M; Li, HS; Li, JM; Min, LJ; Mogi, M; Shiuchi, T; Suzuki, J; Tomochika, H; Tomono, Y; Tsuda, M; Wu, L | 1 |
| Fujimoto, N; Matsumoto, T; Nishii, H; Nomura, M; Ozaki, Y | 1 |
| Fujitani, Y; Hirose, T; Ikeda, F; Kawamori, R; Mita, T; Nakayama, S; Shimizu, T; Uchino, H; Watada, H | 1 |
| Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A | 1 |
4 review(s) available for olmesartan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Endothelium, Vascular; Humans; Imidazoles; Renin-Angiotensin System; Risk Factors; Tetrazoles | 2010 |
Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Humans; Imidazoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Tetrazoles | 2012 |
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Humans; Imidazoles; Randomized Controlled Trials as Topic; Tetrazoles | 2012 |
[Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Imidazoles; Incidence; Kidney Failure, Chronic; Male; Meta-Analysis as Topic; Metabolic Syndrome; Multicenter Studies as Topic; Placebos; Primary Prevention; Randomized Controlled Trials as Topic; Rats; Rats, Inbred Strains; Risk Factors; Sex Factors; Tetrazoles; Time Factors; Treatment Outcome | 2005 |
30 trial(s) available for olmesartan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Kidney Diseases; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Tetrazoles; Young Adult | 2013 |
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertension; Imidazoles; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Regression Analysis; Renin-Angiotensin System; Tetrazoles; Treatment Outcome | 2013 |
Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Telmisartan; Tetrazoles | 2014 |
Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 2; Electrocardiography; Female; Humans; Imidazoles; Male; Middle Aged; Placebos; Tetrazoles; Ventricular Dysfunction, Left; Ventricular Remodeling; Young Adult | 2014 |
Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome | 2016 |
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Imidazoles; Male; Middle Aged; Oxadiazoles; Prediabetic State; Tetrazoles; Valsartan | 2016 |
Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Essential Hypertension; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome | 2016 |
Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies: A Randomized, Controlled, Clinical Trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Aryldialkylphosphatase; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Isoprostanes; Male; Oxidative Stress; Peroxidase; Tetrazoles | 2016 |
The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Rate; Humans; Imidazoles; Incidence; Male; Middle Aged; Tetrazoles | 2016 |
Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Perindopril; Pulse Wave Analysis; Tetrazoles | 2016 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Circadian Rhythm; Creatinine; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles | 2009 |
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography, Ambulatory; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imidazoles; Middle Aged; Patient Selection; Placebos; Reference Values; Tetrazoles; Young Adult | 2010 |
Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Ankle; Antihypertensive Agents; Body Weight; Calcium Channel Blockers; Deoxyguanosine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypertension; Imidazoles; Lipids; Male; Middle Aged; Tetrazoles | 2009 |
Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
Topics: Aged; Algorithms; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles; Time Factors | 2010 |
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glycemic Index; Humans; Hypertension; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Middle Aged; Tetrazoles | 2010 |
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acid-Binding Proteins; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Treatment Outcome | 2010 |
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Incidence; Insulin Resistance; Intercellular Adhesion Molecule-1; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Single-Blind Method; Tetrazoles; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2011 |
Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asia; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Europe; Female; Humans; Hypertension; Hypoglycemic Agents; Imidazoles; Male; Middle Aged; Office Visits; Predictive Value of Tests; Regression Analysis; Risk Assessment; Risk Factors; Tetrazoles; United States; Young Adult | 2011 |
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Imidazoles; Male; Middle Aged; Tetrazoles; Young Adult | 2011 |
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles | 2011 |
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Hyperkalemia; Hypertension; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Proteinuria; Stroke; Tetrazoles; Treatment Outcome | 2011 |
[Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Imidazoles; Kidney Failure, Chronic; Male; Tetrazoles | 2011 |
Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles; Treatment Outcome | 2012 |
Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Japan; Male; Prospective Studies; Single-Blind Method; Survival Analysis; Tetrazoles; Treatment Outcome | 2012 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome | 2012 |
Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Resistance; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Middle Aged; Telmisartan; Tetrazoles | 2013 |
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cell Count; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelial Cells; Female; Hematopoietic Stem Cells; Humans; Imidazoles; Irbesartan; Male; Middle Aged; Prospective Studies; Tetrazoles | 2005 |
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Tetrazoles | 2006 |
Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus, Type 2; Dihydropyridines; Diuretics; Drug Combinations; Endpoint Determination; Female; Humans; Hydrochlorothiazide; Hypertension; Hypotension, Orthostatic; Imidazoles; Indans; Male; Nitrobenzenes; Piperazines; Posture; Prospective Studies; Tetrazoles | 2008 |
32 other study(ies) available for olmesartan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Role of olmesartan in ameliorating diabetic nephropathy in rats by targeting the AGE/PKC, TLR4/P38-MAPK and SIRT-1 autophagic signaling pathways.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fructose; Imidazoles; Kidney; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Rats; Signal Transduction; Sirtuins; Streptozocin; Tetrazoles; Toll-Like Receptor 4 | 2022 |
Angiotensin receptor blockade with olmesartan alleviates brain pathology in obese OLETF rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Metabolic Syndrome; Obesity; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptors, Angiotensin | 2023 |
Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Hypoglycemic Agents; Imidazoles; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Liver; Liver Diseases; Male; Rats, Wistar; Receptor for Advanced Glycation End Products; Renin-Angiotensin System; Signal Transduction; STAT3 Transcription Factor; Tetrazoles | 2020 |
Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Imidazoles; Male; Middle Aged; Outcome Assessment, Health Care; Sex Factors; Tetrazoles | 2020 |
Predictors for the development of microalbuminuria and interaction with renal function.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Imidazoles; Incidence; Kidney; Male; Middle Aged; Risk Factors; Tetrazoles; Young Adult | 2017 |
[Hypertension. Guidelines recommend fixed combinations].
Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Guideline Adherence; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Medication Adherence; Randomized Controlled Trials as Topic; Tetrazoles | 2014 |
Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Rate; Humans; Imidazoles; Kidney Function Tests; Male; Middle Aged; Peptidyl-Dipeptidase A; Prospective Studies; Renin; Tetrazoles | 2015 |
Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP).
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cost Sharing; Diabetes Mellitus, Type 2; Disease Management; Drug Costs; Female; Health Benefit Plans, Employee; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Imidazoles; Male; Medication Adherence; Metformin; Middle Aged; Rosuvastatin Calcium; Tetrazoles; United States | 2015 |
Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients.
Topics: Amides; Antihypertensive Agents; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Chemokine CXCL12; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Fumarates; Humans; Hydralazine; Imidazoles; In Vitro Techniques; Nitric Oxide Synthase Type III; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tetrazoles; Vascular Endothelial Growth Factor A | 2016 |
Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Humans; Imidazoles; Male; Masked Hypertension; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Tetrazoles; White Coat Hypertension | 2017 |
Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Diabetes Mellitus, Type 2; Dihydropyridines; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Pilot Projects; Tetrazoles; Trichlormethiazide | 2017 |
Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Eating; Endothelium, Vascular; Fatty Liver; Fibrosis; Imidazoles; Insulin Resistance; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; NADPH Oxidases; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Obesity; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1 | 2008 |
Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites; Antioxidants; Blood Glucose; Cyclic N-Oxides; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Oxidative Stress; Pravastatin; Spin Labels; Tetrazoles | 2009 |
Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease.
Topics: Animals; Anti-Bacterial Agents; Arthritis, Reactive; Arthritis, Rheumatoid; Autoimmune Diseases; Bacterial Infections; Calcifediol; Calcitriol; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Imidazoles; Minocycline; Psoriasis; Receptors, Calcitriol; Sarcoidosis; Scleroderma, Systemic; Sjogren's Syndrome; Spondylitis, Ankylosing; Tetrazoles; Thyroid Diseases; Uveitis | 2009 |
Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Hypoxia; Imidazoles; Male; Mice; Mice, Obese; Myocytes, Cardiac; Nifedipine; Secondary Prevention; Tetrazoles; Ventricular Remodeling | 2010 |
Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Imidazoles; Tetrazoles | 2011 |
The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Metabolic Syndrome; Risk Factors; Tetrazoles; Treatment Outcome | 2011 |
Diabetes: ROADMAP: the road to renoprotection?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazoles; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Treatment Outcome | 2011 |
Olmesartan, microalbuminuria, and type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Imidazoles; Tetrazoles | 2011 |
Olmesartan, microalbuminuria, and type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; Imidazoles; Tetrazoles | 2011 |
Olmesartan, microalbuminuria, and type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; Imidazoles; Tetrazoles | 2011 |
Olmesartan, microalbuminuria, and type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; Imidazoles; Tetrazoles | 2011 |
L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Male; Tetrazoles | 2011 |
"ROADMAP" controversies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Imidazoles; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; United States; United States Food and Drug Administration | 2011 |
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Hydralazine; Hydrochlorothiazide; Imidazoles; Juxtaglomerular Apparatus; Male; Membrane Proteins; Podocytes; Rats; Rats, Inbred OLETF; Reserpine; Tetrazoles | 2012 |
Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Asian People; Diabetes Mellitus, Type 2; Drug Resistance; Female; Glucose Clamp Technique; Humans; Hypertension; Imidazoles; Insulin Resistance; Japan; Male; Middle Aged; Receptor Cross-Talk; Tetrazoles | 2012 |
Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazoles; Prevalence; Randomized Controlled Trials as Topic; Tetrazoles | 2012 |
Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.
Topics: Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Type 2; Exercise Tolerance; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle, Skeletal; Oxidative Stress; Tetrazoles | 2013 |
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Ascorbic Acid; Blood Glucose; Captopril; Diabetes Mellitus, Type 2; Female; Free Radical Scavengers; Humans; Imidazoles; In Vitro Techniques; Male; Middle Aged; Neutrophils; Superoxide Dismutase; Superoxides; Tetrazoles; Thiazepines | 2005 |
Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites; Antioxidants; Azetidinecarboxylic Acid; Blood Glucose; Calcium Channel Blockers; Cyclic N-Oxides; Deoxyglucose; Diabetes Mellitus, Type 2; Dihydropyridines; Glucose Intolerance; Glucose Tolerance Test; Glucose Transporter Type 4; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Phosphoproteins; Spin Labels; Superoxides; Tetrazoles | 2006 |
An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Exploratory Behavior; Female; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Inbred Strains; Motor Activity; Reaction Time; Receptor, Angiotensin, Type 1; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Species Specificity; Tetrazoles; Time Factors | 2007 |
Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Inflammation; Japan; Male; Metabolic Syndrome; Middle Aged; Telmisartan; Tetrazoles | 2008 |